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 ABSTRACT 
 Objective  Nephrogenic systemic fi brosis (NSF) is 
a generalised fi brotic disorder occurring in certain 
individuals with renal insuffi ciency exposed to gadolinium-
based contrast agents (GdBCA) for MRI. Histopathological 
examination of affected tissues shows increased numbers 
of activated macrophages. To elucidate the mechanisms 
responsible for macrophage activation, the effects of the 
GdBCA Omniscan on normal human macrophage global 
gene expression, chemokine production and nuclear 
factor κB (NFκB) activation was examined. 
 Methods  Normal human monocyte-derived 
macrophages were incubated with Omniscan (50 mM) 
and their gene expression analysed by microarrays 
and real-time PCR. Macrophage chemokine production 
was assayed by multiplex ELISA. NFκB activation was 
assessed by NFκB nuclear localisation and quantitation 
of intracellular levels of inducible nitric oxide synthase 
(iNOS) protein. A specifi c cell-permeable NFκB peptide 
inhibitor was used to abrogate NFκB stimulation of 
chemokine and iNOS protein levels. CCL8/MCP-2 in 
affected skin of patients with NSF was examined by 
indirect immunofl uorescence. 
 Results  Omniscan caused a profound change in 
the transcriptome of differentiated human normal 
macrophages in vitro, including a large increase in the 
expression of genes encoding CC and CXC chemokines. It 
induced rapid nuclear localisation of NFκB and stimulation 
of iNOS protein levels and chemokine production which 
were blocked by an NFκB inhibitory peptide. CCL8/
MCP-2, the most upregulated chemokine following in 
vitro macrophage exposure to Omniscan, was strongly 
increased in NSF-affected skin. 
 Conclusion  The GdBCA Omniscan induces potent 
stimulation of macrophage gene expression, NFκB 
activation and increased NFκB-mediated production of 
CC and CXC chemokines and iNOS. These alterations may 
play a crucial role in the pathogenesis of NSF. 
 INTRODUCTION 
 Nephrogenic systemic ﬁ brosis (NSF), previously 
known as nephrogenic ﬁ brosing dermopathy, is a 
generalised ﬁ brotic disorder occurring in individu-
als with renal insufﬁ ciency following exposure 
to gadolinium-based contrast agents (GdBCA) 
used to enhance MRI.  1  –  5  Clinically, NSF displays 
many similarities to the clinical manifestations of 
systemic sclerosis including severe and usually pro-
gressive skin induration, progressive and eventually 
incapacitating joint ﬂ exion contractures and ﬁ brotic 
involvement of numerous internal organs including 
lungs, heart, diaphragm and striated muscles.  1  –  8  
The association of NSF with GdBCA administra-
tion has been supported by extensive clinical and 
epidemiological studies describing the onset of 
NSF in close temporal relationship with GdBCA 
use  9  –  14  and the presence of Gd in affected tissues 
from patients with NSF.  15  –  18  Furthermore, potent 
functional effects of GdBCA have recently been 
described on human peripheral blood monocytes,  19  
human skin organ cultures  20   and cultured human 
dermal ﬁ broblasts.  21 ,  22  
 Following intravenous administration, GdBCA 
distribute rapidly through the intravascular and 
extracellular space compartments and Gd che-
lates are excreted by glomerular ﬁ ltration, with 
>95% excreted by 1 day, a biological elimination 
half-life of approximately 1.5 h and no detectable 
biotransformation, decomposition or serum pro-
tein binding.  23  ,  24  Because of the renal excretion of 
these compounds and the demonstrated deposition 
of Gd in affected tissues of patients with NSF, the 
accumulation of Gd in tissues in patients with renal 
insufﬁ ciency is believed to be a crucial event in the 
pathogenesis of this condition. Histopathological 
studies of tissues from affected individuals with NSF 
suggest that, during the early stages of the disease, 
the cellular elements involved in the pathogenesis of 
NSF are activated macrophages  7  and bone marrow-
derived collagen-producing ﬁ brocytes that inﬁ ltrate 
the affected tissues.  25  ,  26  We examined whether 
GdBCA could exert a direct effect on human macro-
phage function and found that Omniscan, the 
GdBCA studied, causes a remarkable change in the 
transcriptome of normal human macrophages with 
a potent stimulation of macrophage chemokine 
gene expression and production and activation of 
the nuclear factor κB (NFκB) pathway. We further 
demonstrated that CCL8/MCP-2 was the most up-
regulated chemokine in Omniscan-treated macro-
phages and was also markedly increased in NSF 
affected skin. The multifunctional cytokines and 
chemokines released from normal macrophages 
upon exposure to Omniscan may be able to recruit 
circulating mononuclear cells and ﬁ brocytes and 
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on an Affymetrix GeneChip Scanner 3000 using GeneChip 
Operating Software version 3.0. Raw data were normalised 
using Robust Multichip Average and normalised to control 
samples with GeneSpring GX v7.3.1 and GX 10.0 software 
(Agilent). A volcano plot was used to identify differentially 
expressed genes using parametric testing assuming equal 
variances and no multiple testing correction. Pathway analy-
sis of differentially expressed genes was performed employ-
ing Ingenuity software (Ingenuity Systems, Redwood City, 
California, USA). 
 Real-time PCR validation 
 Expression levels of CCL2 (MCP-1), CCL8 (MCP-2), CXCL10 
(IP10) and CXCL11 (ITAC) were assayed by real-time quanti-
tative PCR using SYBR Green chemistry (Applied Biosystems, 
Foster City, California, USA) following a standard ampli-
ﬁ cation protocol on an ABI Prism 7900 Sequence Detection 
System (Applied Biosystems). The following primers were 
employed: 
 β-Actin: forward 5′-TTGCCGACAGGATGCAGAA-3′, reverse 
5′-GCCGATCCACACGGAGTACTT-3′; CCL2 – chemokine, CC 
motif, ligand 2: forward 5′-ACCAGCAGCAAGTGTCCCAAA-3′, 
reverse 5′-TTTGCTTGTCCAGGTGGTCCAT-3′; CCL8 – chemokine, 
CC motif, ligand 8: forward 5′-TCATGCTGAAGCTCACAC
CCTT-3′, reverse 5′-AGAATTGCCATTGCACAACTCTT-3′; 
CXCL10 – chemokine, CXC motif, ligand 10:  forward 5′-ACTGCC
ATTCTGATTTGCTGCC-3′, reverse 5′-TGATGCAGGTACAGC 
GTACAGT-3′; CXC11 – chemokine, CXC motif, ligand 11: 
forward 5′-ACTCCTTCC AAGAAGAGCAGCA-3′, reverse 
5′-CCATGCCCTTCACACTCATGTT-3′. 
 Relative quantiﬁ cation was performed by arbitrarily setting 
the expression level of the PBS negative control at 100 and by 
expressing changes in transcript levels of other samples relative 
to this control sample. Relative differences in each PCR sample 
were corrected using human β-actin mRNA as an endogenous 
control. Some experiments were performed employing termi-
nally differentiated macrophages without prior activation (not 
exposed to PMA) to conﬁ rm that the observed effects were not 
dependent on PMA activation. Other experiments were per-
formed with macrophages incubated with 500 μM caldiamide 
to exclude any potential effects that the chelator present in the 
Omniscan preparations might have caused on the macrophage 
chemokine gene expression. 
 Multiplex ELISA 
 SearchLight proteome array analyses (Pierce Biotechnology, 
Woburn, Massachusetts, USA) were conducted to measure the 
levels of CCL8, CXCL10, CCL2 and CXCL11 in culture super-
natants from terminally differentiated and activated mac-
rophages following incubation with 50 mM Omniscan for 24 
h.  29  Brieﬂ y, culture supernatant samples were diluted 1:2, 1:50 or 
1:1000 and then incubated for 1 h on the array plates which had 
been prespotted with capture antibodies speciﬁ c for each pro-
tein. The plates were decanted and washed three times with PBS 
before addition of a mixture of biotinylated detection antibod-
ies to each well. Following incubation with detection antibodies 
for 30 min, the plates were washed three times and incubated 
for 30 min with streptavidin horseradish peroxidase. The plates 
were again washed and SuperSignal Femto chemiluminescent 
substrate (Pierce Biotechnology) was added. The plates were 
immediately imaged using the SearchLight imaging system and 
data were analysed using ArrayVision software (GE Healthcare, 
Chalfont St Giles, UK). 
activate tissue resident ﬁ broblasts to initiate a ﬁ brotic process as 
discussed recently.  19  ,  22 ,  27  Thus, the data presented here indicate 
that the stimulation of chemokine production and activation of 
the NFκB pathway in macrophages may play a crucial role in the 
pathogenesis of NSF. 
 MATERIALS AND METHODS 
 Macrophage isolation and differentiation 
 Normal human peripheral blood buffy coat  preparations 
or leuko-reduction ﬁ lters were obtained from the Thomas 
Jefferson University Hospital Blood Bank following 
Institutional Review Board approval. Human peripheral blood 
mononuclear cells (PBMCs) were isolated from the buffy coat 
or the leukoreduction ﬁ lters by Ficoll-Hypaque gradient cen-
trifugation (Amersham Pharmacia Biotech, Piscataway, New 
Jersey, USA) and enriched for monocytes by adherence to 
plastic culture dishes for 2 h as described.  28  To obtain termi-
nally differentiated macrophages the monocytes were cultured 
with 60 ng/ml M-CSF (BioVision, Mountain View, California, 
USA) and 25 ng/ml interleukin 10 (IL-10) (BioVision) for 7 days 
as described.  28  Macrophages were activated by incubation in 
the same medium for an additional 24 h with 50 nM phor-
bol myristate acetate (PMA; Acros Organics, Morris Plains, 
New Jersey, USA). Activated macrophages (5 × 10  5  cells/ml) 
were exposed for 24 h to 50 mM Omniscan (GE Healthcare, 
Lawrence, Massachusetts, USA). No signiﬁ cant effects on cell 
numbers or increased cytotoxicity were observed as exam-
ined by the WST-1 assay (Roche Diagnostics, Indianapolis, 
Indiana, USA). Certain experiments were performed with 
differentiated macrophages prepared exactly as described 
above except that they were not activated by culture with 
PMA. Macrophage samples cultured with an equal volume of 
phosphate buffered saline (PBS) served as negative controls. 
Macrophage culture supernatants were isolated and ﬁ ltered 
and maintained frozen for subsequent studies. Isolation of 
total RNA from macrophages was performed as previously 
described for human monocytes.  19  The Omniscan employed 
for all the studies was tested and veriﬁ ed by the manufacturer 
to be free from endotoxin contamination. The endotoxin-
free status of Omniscan was further conﬁ rmed utilising the 
Etoxate Assay (Sigma-Aldrich, St Louis, Missouri, USA) based 
on Limulus Ameobocyte Lysate (LAL) gel formation, accord-
ing to the manufacturer’s instructions. 
 Analysis of global gene expression patterns 
 Global gene expression analysis was performed employing 
microarrays. For this purpose macrophages from two differ-
ent donors prepared and activated as described above were 
incubated for 24 h with either PBS or 50 mM Omniscan. Total 
RNA was extracted using the RNeasy protocol from Qiagen 
(Valencia, California, USA). RNA quality was evaluated using 
the Agilent 2100 Bioanalyzer (Agilent, Palo Alto, California, 
USA). Total RNA (2 μg) from control and Omniscan-treated 
samples (two replicates in each group) were used for 
Affymetrix one cycle target labelling as described by the man-
ufacturer (Affymetrix, Santa Clara, California, USA). Each of 
four Affymetrix HG U133 plus 2.0 arrays were hybridised for 
16 h with biotin-labelled fragmented cRNA (10 μg) in 200 μl 
hybridisation mixture according to the manufacturer’s proto-
col. Arrays were washed and stained using GeneChip Fluidic 
Station 450 and hybridisation signals were ampliﬁ ed using 
antibody ampliﬁ cation with goat IgG (Sigma-Aldrich) and 
anti-streptavidin biotinylated antibody. Chips were scanned 
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each incubation with three changes of PBS for 2 min each. 
Tissue sections or ﬁ xed cells were then counterstained with 
4’,6-diamidino-2-phenylindole (DAPI) and analysed using a 
Zeiss LSM 510 META Confocal Laser Scanning Microscope 
System. Zeiss META confocal microscopy software was used 
in balancing signal strength. The breakthrough of the DAPI 
signal into the red and green channels was recorded separately 
and subtracted from the DAPI blue channel. Each image was 
scanned eight times to accurately separate signal from noise. 
Panels were assembled using Adobe Photoshop software 
without any RGB modiﬁ cation. Quantitative analysis of ﬂ uo-
rescence was performed using ImageJ software (NIH National 
Institute of Mental Health, Bethesda, Maryland, USA). The 
integrated density of ﬂ uorescence was calculated in three 
biopsies and expressed as mean±SD. An unpaired two-tailed t 
test was used to calculate p values. 
 NFκB inhibition studies 
 To demonstrate the participation of NFκB activation in the 
observed results, macrophages exposed to Omniscan were 
pretreated by incubation with a cell-permeable NFκB inhibi-
tory peptide.  30    31  The inhibitory peptide was the Iκκ-NBD pep-
tide, which consists of an antennapedia (AP) homeodomain 
that confers cell permeability, and the T735 to E745 region 
of Iκκβ which is the NEMO binding domain. This peptide 
blocks the interaction of NEMO, an IκB complex regulatory 
protein, with the IκB complex. The control peptide consists 
of the AP homeodomain sequence alone. The Iκκ-NBD and 
control peptides (Marligen Biosciences, Ijamsville, Maryland, 
USA) were dissolved in dimethyl sulphoxide to a concentra-
tion of 6.7 mM. Cells were washed with PBS and exposed 
to 200 μM of either Iκκ-NBD or the control peptide for 2 h. 
This incubation was followed by addition of either PBS or PBS 
with 5, 10, 25 or 50 mM Omniscan for 30 min. Cells were 
washed twice in PBS and lysed in 1 ml iNOS buffer. iNOS 
protein levels were determined by ELISA as described above. 
In other experiments the effects of the cell-permeable NFκB 
inhibitory peptide on chemokine expression by macrophages 
incubated either in PBS alone or exposed to 50 mM Omniscan 
were examined. 
 Quantitative assessment of iNOS protein levels 
 Terminally differentiated macrophages were exposed to various 
concentrations of Omniscan (5–50 mM) for 90 min and the intra-
cellular levels of inducible nitric oxide synthase (iNOS) protein 
were examined in cell lysates of control and Omniscan-treated 
cells. The amounts of iNOS present in the macrophage samples 
were measured with the Quantising human iNOS ELISA kit 
(R&D Systems, Minneapolis, Minnesota, USA) according to the 
manufacturer’s protocol. The values of iNOS protein present in 
the samples were expressed as U/ml of cellular lysates by com-
parison with a standard curve prepared employing recombinant 
iNOS protein provided by the manufacturer. The calculations 
were performed within the linear range of the standard curve 
for all samples. 
 Indirect immunofl uorescence studies 
 CCL-8 protein was analysed in a sample of normal skin 
obtained from a healthy individual and in affected skin 
from three different patients with NSF by immunoﬂ uores-
cence using a speciﬁ c anti-CCL8 rabbit polyclonal antibody 
(ABCAM, Cambridge, Massachusetts, USA). Isotype control 
staining was performed using rabbit IgG (Sigma, St Louis, 
Missouri, USA). For NFκB localisation studies, macrophages 
were exposed to Omniscan or saline for 30 min and then ﬁ xed 
and permeabilised. Anti-p65-NFκB antibodies (Cell Signaling, 
Danvers, Massachusetts, USA) were used at a 1:100 dilu-
tion according to the manufacturer’s instructions. Secondary 
antibodies were afﬁ nity puriﬁ ed sheep FAB′ anti-rabbit IgG, 
Cy3 conjugated (Sigma, St Louis, Missouri, USA). Parafﬁ n-
embedded sections from skin were deparafﬁ nated with two 
changes of xylene for 10 min each and then two changes of 
ethanol for 5 min each. For antigen retrieval the tissue sections 
were boiled in 10 mM citrate buffer pH 6.0 for 20 min. The 
sections were then rinsed in PBS for 2 min and incubated with 
5% (w/v) normal sheep serum for 20 min at room tempera-
ture to block non-speciﬁ c binding sites. The primary antibody 
incubation step was performed in a dark humidiﬁ ed cham-
ber overnight at 4°C for CCL8. Tissue sections were then 
incubated with the sheep polyclonal antibodies (1:200). The 
unbound antibodies were removed from the section following 
 Figure 1  (A) Dendrogram showing gene expression differences induced by 50 mM Omniscan in normal human differentiated macrophages. RNA 
was isolated from replicate samples of normal human differentiated macrophages incubated under control conditions (C1 and C2) or cultured with 
50 mM Omniscan (G1 and G2), labelled and applied to Affymetrix human U133 2.0 Plus microarrays. Dendrograms are refl ective of the genes with a 
differential expression of more than twofold in the two experimental conditions. In the dendrogram shown, a shorter arm indicates higher similarity 
whereas a longer arm indicates lower similarity. (B) Volcano plot of differentially expressed transcripts in the presence of Omniscan. There are four 
positive and four negative relative expression values (VG) and log 2 (fold change) shown on the x-axis of the fi gure. The y-axis is negative base 10 
logarithm of the p value for the gene F test (F1). Genes that are signifi cant at the 0.05 multiple test adjusted level are shown in red. Several transcripts 
of interest exhibiting twofold or greater increases of expression with p values <0.05 in Omniscan-exposed cells are indicated by arrows. 
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(MCP-2), CXCL10 (IP10), CXCL11 (ITAC) and CXCL12 (SDF1) 
on the same samples employed for the microarray studies. The 
results conﬁ rmed and quantiﬁ ed the microarray results, indi-
cating that expression of these genes was increased in normal 
differentiated and activated human macrophages in response 
to exposure to 50 mM Omniscan ( ﬁ gure 3A ). Omniscan caused 
a potent stimulation of the expression of CCL8 (669±108-fold 
increase), CXCL10 (401±72-fold increase), CCL2 (245±36-fold 
increase) and CXCL11 (551±48-fold increase) compared with 
the PBS control levels. To examine whether previous PMA 
activation of macrophages was required for Omniscan stimu-
lation of chemokine expression, four similar experiments were 
performed with macrophages without PMA stimulation. The 
results in  ﬁ gure 3B show that PMA activation is not required to 
elicit the potent stimulation of chemokine expression in mac-
rophages following exposure to Omniscan, and that the pattern 
of chemokine stimulation was qualitatively similar between 
samples obtained from Omniscan-exposed macrophages with 
or without previous PMA activation. Studies with macrophages 
cultured with caldiamide showed that the chelator alone had 
no detectable effects on macrophage chemokine gene expres-
sion (data not shown). No toxic effects were observed in the 
macrophages exposed to 50 mM Omniscan, as indicated by 
the absence of cytotoxicity in WST-1 soluble tetrazolium cyto-
toxicity assays and the observation of similar levels of house-
keeping gene transcripts in quantitative PCR arrays (data not 
shown). 
 RESULTS 
 Global gene expression of control and Omniscan-exposed 
normal human macrophages 
 Comparison between the average gene expression signals for 
the replicates between Omniscan-exposed and control macro-
phages revealed 551 differentially expressed genes (more than 
twofold) ( ﬁ gure 1A ). Table 1 in the online supplement shows a 
list of all the differentially expressed genes. In many instances 
the differential expression was of a large magnitude (up to 
19-fold). A volcano plot analysis of the differentially expressed 
transcripts ( ﬁ gure 1B ) revealed that 240 of them were upregu-
lated and 311 were downregulated by more than twofold with 
high statistical signiﬁ cance (p<0.05). Of these 240 upregulated 
transcripts, 31 had a signal intensity >100 and corresponded 
to genes with a known function on the NCBI database. We 
deﬁ ned the transcripts for these 31 genes as representing the 
‘macrophage Gd signature’. Five of these 31 transcripts cor-
responded to chemokines and three to interferon-inducible 
genes. The complete list is shown in  ﬁ gure 2 . CEL ﬁ les for all 
the samples analysed will be made publicly available through 
the NCBI following publication. 
 Real-time PCR validation 
 To validate the microarray results and to further characterise 
the chemokine expression levels in macrophages following 
incubation with Omniscan, we performed real-time quantita-
tive PCR analysis of mRNA levels for CCL2 (MCP-1), CCL8 
 Figure 2  The macrophage Gd signature genes. Comparisons were performed between transcript expression levels of cells exposed to 50 mM 
Omniscan and phosphate buffered saline (PBS) control macrophages on the Affymetrix U133 2.0 Plus microarray, which yielded a group of 31 
transcripts excluding orphan genes and transcript redundancies. Genes were considered signifi cant if the p value of the differences was <0.05, the 
signal intensity of their expression was >100 and the fold change average signal intensity was >2. Highlighted in red are transcripts for chemokines 
of the interferon pathway. 
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skin from three patients with NSF. Immunoﬂ uorescence stud-
ies followed by quantitative confocal microscopy analysis 
showed that, in contrast to normal skin from a healthy indi-
vidual, affected skin from three patients with NSF displayed a 
marked increase in the level of ﬂ uorescence for MCP-2/CCL8 
( ﬁ gure 4A ); the increase was apparent in both the upper and 
lower dermis and was consistent in the three biopsies exam-
ined (p<0.0001,  ﬁ gure 4B ). 
 Pathway analysis of microarray data revealed strong NFκB 
activation 
 Pathway analysis of all the signiﬁ cantly (more than twofold, 
p<0.05) differentially increased genes in the transcriptome of 
Omniscan-treated macrophages indicated a strong activation of 
the NFκB pathway ( ﬁ gure 5 ). All the macrophage chemokines 
found to be upregulated in response to Omniscan exposure are 
downstream targets of NFκB activation. Given the strong NFκB 
pathway activation suggested by these results, all reagents were 
 Multiplex ELISA of tissue culture supernatants from microarray 
studies 
 Culture media isolated from normal human differentiated and 
activated macrophages exposed to 50 mM Omniscan were anal-
ysed by the Searchlight Proteome Array Assay. Consistent with 
the mRNA expression results, we observed a marked increase in 
the production and secretion of various chemokines compared 
with the levels from control macrophages incubated with PBS. 
The concentrations of selected cytokines found in the culture 
medium of Omniscan-stimulated macrophages are shown in 
 ﬁ gure 3C . 
 MCP-2/CCL8 expression is increased in NSF skin 
 To further validate the in vitro results and to determine 
whether the observed increase in chemokine production was 
pertinent to the pathogenesis of NSF, we examined the expres-
sion of MCP-2/CCL8, the most upregulated chemokine in the 
microarray, in parafﬁ n-embedded skin biopsies from affected 
 Figure 3  Effects of Omniscan on the expression and production of chemokines in normal human differentiated macrophages. (A) mRNA expression 
levels of four chemokines following treatment of phorbol myristate acetate (PMA)-activated macrophages with 50 mM Omniscan for 24 h. Results 
are expressed as mean±SD percentage difference of three replicate samples analysed by quantitative RT-PCR. The phosphate buffered saline 
(PBS) control was arbitrarily set to 100% expression. (B) mRNA levels of four chemokines expressed by non-PMA-activated macrophages following 
incubation with Omniscan. (C) Levels of secreted chemokines assessed by multiplex ELISA in the supernatants from PMA-activated macrophages 
cultured under the same conditions as in (A). The results are expressed as pg/ml of samples analysed in duplicate, each at three different dilution; 
***p<0.01. 
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as early as 5 min after macrophage incubation with 50 mM 
Omniscan, a striking NFκB nuclear localisation was observed, 
indicating a strong activation of this pathway. The observed 
nuclear localisation was completely abrogated by pretreatment 
of the macrophages with a cell-permeable NFκB inhibitory (Iκκ-
NBD) peptide ( ﬁ gure 6B ) but was not changed by pretreatment 
with the AP control peptide. 
 Omniscan stimulated iNOS protein levels in differentiated 
normal human macrophages through NFκB activation 
 To further conﬁ rm the activation of NFκB, we measured the levels 
of iNOS protein in cell lysates from differentiated macrophages 
without prior PMA activation following incubation with vari-
ous concentrations (5–50 mM) of Omniscan ( ﬁ gure 6C,D ). The 
basal level of iNOS in control macrophages was ~0.015 U/ml of 
cell lysate. Following 30 min incubation with all concentrations 
of Omniscan there was a potent increase in iNOS levels (10- to 
25-fold) with a dose response that reached a plateau at 25 mM 
( ﬁ gure 6C ). To examine the role of NFκB in the stimulation of 
iNOS protein levels, the effects of NFκB inhibition by pretreat-
ment with the inhibitory Iκκ-NBD peptide were analysed. The 
results are shown in  ﬁ gure 6D . Exposure to Omniscan caused 
a concentration-dependent increase in iNOS protein levels, 
with 5 mM inducing a 36-fold increase and 50 mM a 157-fold 
increase. This stimulation was essentially completely abolished 
by incubation with the Iκκ-NBD inhibitory peptide but was not 
affected by the AP control peptide. 
 Omniscan stimulation of chemokine gene expression is 
dependent on NFκB activation 
 To determine whether NFκB activation was required for 
Omniscan stimulation of macrophage chemokine production, 
terminally differentiated macrophages without prior PMA stim-
ulation were preincubated with the NFκB cell-permeable inhibi-
tory peptide and then exposed to Omniscan (50 mM) for 24 h. 
Quantitative assessment of transcript levels showed that pre-
treatment with the Iκκ-NBD peptide completely abrogated the 
Omniscan-induced upregulation of CCL8, CXCL10 and CXCL11 
and reduced by ~85% the upregulation of CCL2  ( ﬁ gure 6E ). 
These results demonstrated that exposure to Omniscan elicits 
potent chemokine gene expression stimulation in macrophages 
that is dependent on NFκB activation but independent of prior 
PMA activation. 
 DISCUSSION 
 The activation of tissue macrophages is known to play a criti-
cal role during the wound healing process, orchestrating both 
the onset and the resolution of the ﬁ brotic phase.  32  –  34  The study 
of the pathological processes occurring in systemic ﬁ brotic 
diseases such as systemic sclerosis has revealed the presence 
of macrophages in the affected tissues, particularly during the 
early stages of tissue involvement.  35    36  Macrophage inﬁ ltration 
has also been described in the affected skin of patients with 
NSF,  7  and electron scanning microscopy and energy dispersive 
x-ray spectroscopy revealed intracellular Gd deposits in macro-
phages in affected NSF skin.  15  These elegant studies, however, 
did not provide any functional evidence that the Gd deposits 
caused functional effects or alterations in the macrophage cell 
populations. 
 The studies described here examined directly the role of an 
interaction between GdBCA and macrophages by exposing nor-
mal differentiated human macrophages to the GdBCA Omniscan. 
conﬁ rmed to be endotoxin-free using a LAL gel formation assay 
(data not shown). 
 Omniscan induced NFκB nuclear localisation in terminally 
differentiated macrophages 
 To conﬁ rm functionally the NFκB activation suggested by the 
pathway analysis, we examined the effects of Omniscan on 
NFκB nuclear localisation in normal macrophages. As shown 
in  ﬁ gure 6A , in macrophages incubated under control condi-
tions the localisation of NFκB is mostly cytoplasmic. In contrast, 
 Figure 4  Confocal microscopy imaging of MCP-2/CCL8 expression 
in the skin of patients with nephrogenic systemic fi brosis (NSF). (A) 
Affected skin samples from three different individuals with NSF were 
examined for MCP-2/CCL8 tissue expression with similar results. The 
results of one illustrative patient are shown. MCP-2/CCL8 antibodies 
(ABCAM) are stained in red. Nuclei are counterstained with DAPI in 
blue. Note the intense staining in both the upper and lower dermis of 
the NSF biopsy whereas normal skin displays only a dim fl uorescence 
for MCP-2, mostly around a vessel in the lower dermis. Original 
magnifi cation 200×. (B) Quantitative analysis of MCP-2/CCL8 antibody 
fl uorescence in skin samples from a normal control and from three 
patients with NSF. The integrated density of fl uorescence (IDF) of the 
normal skin (open bar) is compared with the average IDF of the three 
NSF skin biopsies (closed bar) and the values are expressed as arbitrary 
IDF units (p<0.0001). 
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used here are substantially higher than those found in the circu-
lation of individuals with normal renal function following their 
administration for imaging studies, the actual concentrations 
of these compounds in the tissues of patients with renal insuf-
ﬁ ciency are very likely to be much greater than those calcu-
lated from pharmacokinetic studies. For example, in a study of 
patients with chronic renal failure on haemodialysis receiving 
0.1 mmol/kg administrations of Gd-DTPA (Magnevist) before 
haemodialysis, serum concentrations as high as 50 μmol Gd/
ml were observed.  37  Furthermore, recent studies have demon-
strated the selective accumulation of Gd in macrophages and 
ﬁ brocytes in affected skin from patients with NSF,  15  suggest-
ing that the distribution of GdBCA in affected tissues is not 
homogeneous and that GdBCA can be concentrated in tissue 
macrophages resulting in cellular exposure to much higher con-
centrations of these compounds. 
 The reasons why only certain individuals with renal insuf-
ﬁ ciency exposed to GdBCA develop NSF are not known. 
However, it is very likely that there is great variability in the 
cellular response to GdBCA among individuals. Indeed, in 
our previous study  19  we observed that PBMCs from different 
donors display different patterns of activation following incuba-
tion with similar concentrations of the same contrast agent. We 
have suggested that this variation must be related to a permis-
sive genetic background that may inﬂ uence the threshold and 
the pattern of cellular activation. 
This compound was chosen because it is the most common 
GdBCA to which patients who subsequently developed NSF 
had been exposed. Another reason for our focus on this GdBCA 
was that, in a previous study, we performed a detailed com-
parison of several GdBCA on PBMC function  19  and found that, 
despite numerous quantitative and qualitative differences in the 
levels of cytokine/chemokine stimulation between the different 
GdBCA, the most potent effects were observed with Omniscan. 
However, we also performed a microarray analysis on termi-
nally differentiated normal human macrophages incubated with 
another GdBCA, Gd-DTPA. The effects of Omniscan were sub-
stantially stronger in inducing macrophage activation than those 
induced by Gd-DTPA. 
 The microarray analysis of transcriptome changes occur-
ring in normal human macrophages as a result of exposure to 
Omniscan demonstrated a remarkable change in their transcrip-
tome that results in the differential expression of 551 genes, as 
depicted in  ﬁ gure 1 and listed in table 1 in the online supple-
ment. Although the Gd-DTPA data are not described, a table of 
the differentially expressed genes in human macrophages fol-
lowing Gd-DTPA stimulation is included in table 2 in the online 
supplement. A volcano plot analysis of the most differentially 
expressed genes following macrophage exposure to Omniscan 
revealed the increased expression of genes encoding numerous 
chemokines known to be potent chemoattractants for bone 
marrow-derived cells. Although the concentrations of GdBCA 
 Figure 5  Pathway analysis of Omniscan upregulated transcripts. Ingenuity software pathway analysis of the genes most upregulated by Omniscan 
indicated that the most represented pathway was the nuclear factor κB (NFκB) signalling pathway. The upregulated genes represented in the 
pathway are shown in blue symbols according to Ingenuity classifi cation. 
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chemokines in response to Omniscan exposure, we analysed the 
cluster of upregulated genes by pathway analysis. This analysis 
indicated that most of the chemokines found to be increased 
following GdBCA exposure are known to be induced as a result 
of the activation of NFκB ( ﬁ gure 5 ). To determine whether the 
observed macrophage activation was caused by stimulation of 
the NFκB pathway we analysed the nuclear localisation of NFκB 
and the levels of iNOS in differentiated macrophages following 
incubation with Omniscan ( ﬁ gure 6 ). We observed that 5 min 
incubation was sufﬁ cient to induce essentially complete nuclear 
localisation of NFκB, indicating a strong activation of this path-
way. Furthermore, Omniscan induced a potent dose-dependent 
stimulation of iNOS protein levels and chemokine production 
in the same cells. Inhibition of intracellular NFκB with a cell-
permeable inhibitory peptide showed that NFκB activation was 
 The results shown in  ﬁ gure 3A conﬁ rmed and quantiﬁ ed the 
results of the microarray experiments indicating that the expres-
sion of numerous chemokine genes was increased in normal 
differentiated human macrophages. Furthermore, the results 
shown in  ﬁ gure 3B show that these effects were independent 
of PMA macrophage activation. Assessment of chemokine 
protein levels in media of GdBCA-exposed macrophages con-
ﬁ rmed the increase in production of CCL8, CCL2, CXCL9 and 
CXCL11 ( ﬁ gure 3C ). Most importantly, immunoﬂ uorescence 
studies with confocal microscopy of affected skin from three 
patients with NSF indicated that CCL8, the most upregulated 
chemokine, was markedly increased in comparison with normal 
skin ( ﬁ gure 4A,B ). 
 To gain an insight into the mechanisms responsible for the 
remarkable increase in the macrophage production of these 
 Figure 6  Cellular localisation of nuclear factor κB (NFκB) in Omniscan-treated differentiated macrophages and Omniscan stimulation of macrophage 
inducible nitric oxide synthase (iNOS) protein levels and chemokine production through NFκB activation. (A) Omniscan induction of NFκB nuclear 
localisation. Confocal microscopy analysis of terminally differentiated macrophages exposed to 50 mM Omniscan (Gado) for 5 min or maintained 
in phosphate buffered saline (PBS). Staining for NFκB p65 was shifted into the nuclei in the Omniscan-treated cells within 5 min of exposure. (B) 
Inhibition of nuclear localisation of NFκB p65 by pretreatment with the inhibitory Iκκ-NBD peptide. Panels are representative of three different 
experiments on normal human terminally differentiated macrophages (magnifi cation 200×). Antennapedia homeodomain (AP) peptide alone was used 
as a control peptide. (C) Dose-dependent stimulation of iNOS protein levels by Omniscan. iNOS protein levels following lipopolysaccharide (LPS) and 
Omniscan at concentrations of 5–50 mM were measured. Cells were incubated for 30 min and iNOS protein levels measured in cell lysates using an 
ELISA and calculated by comparison with a standard curve obtained with human iNOS recombinant protein. The assays were performed in triplicate. 
Values are expressed in U/ml according to the instructions from the manufacturer (R&D Systems). (D) Omniscan induction of iNOS protein levels is 
dependent on NFκB activation. iNOS protein levels in terminally differentiated macrophages exposed to either LPS as positive control or Omniscan 
in the presence of a control peptide or of the inhibitory Iκκ-NBD peptide. AP peptide alone was used as control. iNOS protein levels were normalised 
to the values obtained with macrophages treated with LPS in the absence of any peptide. Values are presented as average and SE of triplicates. (E) 
Omniscan stimulation of chemokine expression is dependent on NFκB activation. Chemokine expression in terminally differentiated macrophages 
exposed to either LPS as positive control or Omniscan in the presence of a control peptide or of the inhibitory Iκκ-NBD peptide. AP peptide alone was 
used as control. Percentage expression of chemokines was normalised on macrophages treated with PBS in the absence of any peptide. The other 
values were calculated as multiples thereof. Values are presented as mean and SE of triplicates: ***p<0.01). 
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necessary for the observed increase in iNOS levels and stimula-
tion of chemokine expression in normal macrophages following 
Omniscan exposure. 
 The data reported here show that GdBCA can induce a potent 
activation of normal macrophages and suggest that a similar 
mechanism may be responsible for the macrophage activation 
observed in NSF-affected tissues. Although these observations 
strongly implicate macrophage participation in this unique 
ﬁ brotic process, the role of any cell type in NSF is presumptive 
since no single cell type has been deﬁ nitively demonstrated to 
be responsible for the spectrum of histological and pathologi-
cal changes observed in this condition. Indeed, we consider it 
highly unlikely that a single cell type is responsible for mediat-
ing all the effects of GdBCA in the induction of NSF. However, 
the contention that macrophages may play an important role 
in this process is supported by strong experimental evidence 
indicating that macrophages play a role in wound healing  32  –  34  
and in the pathogenesis of systemic sclerosis.  35    36  The involve-
ment of monocytes and macrophages suggested here does not 
preclude effects of GdBCA on other cells present in lesions such 
as ﬁ brocytes and ﬁ broblasts. Furthermore, it is widely accepted 
that there is an increased number of ﬁ brocytes (CD34) in the 
skin of patients with NSF. These cells are of bone marrow ori-
gin and home to the skin following a speciﬁ c chemokine gradi-
ent. In this sense, a speciﬁ c activation of macrophages causing 
increased production and a gradient of chemokines is very likely 
to occur and to be crucial in the process. 
 Although the studies reported here were conducted in vitro, 
the kinetics of response we observed, including a potent NFκB 
nuclear localisation as early as 5 min following exposure to 
Omniscan, suggest that normal human macrophages are capa-
ble of reacting directly to the Gd-chelate complex. The kinet-
ics of response and the activation of NFκB are similar to those 
observed following lipopolysaccharide stimulation, suggesting 
a possible involvement of Toll-like receptor (TLR) signalling in 
this process. Additional studies are in progress to further exam-
ine the role of TLR signalling in GdBCA-induced macrophage 
activation in the initiation and progression of tissue ﬁ brosis. 
 The results described here show conclusively that Omniscan 
is able to activate macrophages and induce their production of 
numerous chemokines that are known to be involved in the 
pathogenesis of tissue ﬁ brosis. Indeed, we found potent stimula-
tion of chemokines such as CXCL10 which have been shown to 
be raised in the serum of some patients with systemic sclerosis  38  
and to participate in wound healing.  39  Furthermore, we clearly 
demonstrate that the activation responsible for their production 
is NFκB-mediated. Thus, the principal conclusion of the studies 
described here is that the GdBCA Omniscan, when in contact 
with terminally differentiated macrophages, is able to activate 
them towards a proﬁ brotic phenotype and therefore this could 
trigger a sequence of events that is responsible for the develop-
ment of the clinical picture of NSF in a genetically permissive 
background. Most importantly, this paradigm could be used to 
investigate the very early events in the pathogenesis of idio-
pathic tissue ﬁ brotic disorders such as systemic sclerosis or idio-
pathic pulmonary ﬁ brosis, conditions in which the triggering 
events are not known, thus precluding a detailed analysis of the 
early steps in their pathogenesis. In this regard, environmentally-
induced diseases such as GdBCA-induced NSF may offer a very 
valuable model to study the cascade of early events that lead to 
a given pathological ﬁ brotic disease phenotype. 
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